Oppenheimer assumed coverage on shares of Cara Therapeutics (NASDAQ:TVRD - Free Report) in a research report sent to investors on Wednesday, May 21st, MarketBeat.com reports. The brokerage issued an outperform rating and a $65.00 price objective on the stock.
Separately, Wall Street Zen raised Cara Therapeutics to a "hold" rating in a research report on Saturday, May 24th.
Get Our Latest Analysis on TVRD
Cara Therapeutics Price Performance
NASDAQ:TVRD traded down $0.44 on Wednesday, hitting $30.42. The stock had a trading volume of 27,127 shares, compared to its average volume of 20,617. Cara Therapeutics has a 52-week low of $8.13 and a 52-week high of $34.31.
About Cara Therapeutics
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Further Reading
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
